Nick Dearden has been an economic justice campaigner for over 20 years, and his attention was on the pharmaceutical industry when Covid-19 hit. But as the world began to sing the praises of pharmaceutical companies, Nick saw an unprecedented PR coup. Giant corporations capitalised on the crisis, tightening their stranglehold over the health of the […]
Jul 7
Downstream: Masculinity, Modern Love, and Mental Health w/ Blindboy
Blindboy is an artist, podcaster, and author. His storytelling style weaves anti-colonial histories with perspectives on modern masculinity, politics, and mental health, all cut with an absurdist sense of humour. In public Blindboy wears a mask made from a plastic bag, maintainin ... Show More
1h 40m
Jul 1
Downstream: Exposing The True Costs of AI w/ Karen Hao
As AI begins to fundamentally alter our lives, we’re in urgent need of expert voices who both understand how the technology works and are capable of scrutinising its effects. In her new book, Empire of AI, tech reporter and former Silicon Valley engineer Karen Hao debunks the myt ... Show More
1h 29m
Mar 2024
Long Reads: Big Pharma's Toxic Record w/ Nick Dearden
From the HIV/AIDS crisis, to the opioid epidemic, to the COVID-19 pandemic, pharmaceutical corporations have been accused of profiteering at the expense of countless lives. Nick Dearden, director of Global Justice Now and the author of a new book called Pharmanomics: How Big Phar ... Show More
53m 19s
May 2024
This Is a Very Weird Moment in the History of Drug Laws
Drug policy feels very unsettled right now. The war on drugs was a failure. But so far, the war on the war on drugs hasn’t entirely been a success, either.Take Oregon. In 2020, it became the first state in the nation to decriminalize hard drugs. It was a paradigm shift — treating ... Show More
1h 2m
Dec 2023
Opioid Victims Have a Settlement. Will the Supreme Court Undo It?
The opioid epidemic has been one of the biggest public health disasters in generations. The drug company at the heart of the crisis, Purdue Pharma, maker of the prescription painkiller OxyContin, agreed to a multibillion-dollar deal to settle thousands of claims against it — but ... Show More
23m 50s
Sep 2023
Why One Drug Company Held Back a Better Drug
For decades, drugmakers have argued that patents are critical to bringing new drugs to the market. But in 2004, when a promising H.I.V. treatment emerged, Gilead Sciences decided to slow-walk its release to maximize profit on the company’s existing patents.Rebecca Robbins, who co ... Show More
35m 38s